The QualityStocks Daily Wednesday, December 12th, 2018

Today's Top 3 StockMarketWatch

CannabisNewsWire (MCOA) +58.05%

QualityStocks (PRTX) +53.85%

InvestorPlace (DPWW) +43.33%

The QualityStocks Daily Stock List

Gratitude Health, Inc. (GRTD)

Penny Stock Hub, Cannabis Daily, Zacks, Wallet Investor, Simply Wall St, MarketWatch, Investors Hangout, InvestorsHub, Morningstar, Stockhouse, GuruFocus, TradingView, and Barchart reported earlier on Gratitude Health, Inc. (GRTD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Gratitude Health, Inc. manufactures, sells, and markets functional ready-to-drink (RTD) beverages under the Gratitude brand. The Company’s Founders, Mr. Roy Warren and Mr. Andy Schamisso, are beverage veterans with greater than 30 years of experience in the industry. Gratitude Health was created to manufacture healthy, inventive, and certified-organic beverages for a consumer market interested in healthy aging. Formed in 2017, Gratitude Health has its corporate office in North Palm Beach, Florida.

Earlier this year, Gratitude Health announced that it entered into a definitive exchange and spinoff agreement with Vapir Enterprises, Inc., previously traded under the symbol VAPI. The combination facilitated Gratitude Health, Inc. to become a publicly traded company.

With this agreement, Vapir Management retains its operations, intellectual property (IP), assets, and liabilities. It will continue as a separate operating entity and will not be involved in the beverage business.  Vapir is a developer and manufacturer of vaporization devices.

Gratitude Health offers flavored and unsweetened RTD teas. Its alternative food and beverage options are nutrient rich. They feature reduced or eliminated carbohydrate and sugar levels. In addition, they are full of anti-oxidants and organic ingredients. Each bottle contains no more than 45 calories. Gratitude Health’s 16 oz proprietary bottles feature collectible debossed designs intended to be reused and repurposed.

Gratitude Health pan-roasts its tea by hand. Its tea flavors include Dragon Well Green Tea Peach; Dragon Well Green Tea Mint; Dragon Well Green Tea Wildberry; Dragon Well Green Tea Blood Orange; and Dragon Well Green Tea Original. Dragon Well tea (culturally known as "Longjing") comes from the pristine, certified-organic fields of Hangzhou China. Dragon Well tea has the distinction of being named "The Tea of Emperors". It is the most popular in China.

Last month, Gratitude Health announced that it entered into a Distribution Agreement with Dora’s Naturals, Inc. to service its ready-to-drink Gratitude Dragon Well Green Tea into the New York, New Jersey and Connecticut markets. Dora’s Naturals is a privately owned distributor of natural and organic products. Dora’s Naturals of New Jersey delivers to greater than 4,000 store locations in the tri-state area reaching as far south as Virginia and as far north as New Hampshire. 

Gratitude Health, Inc. (GRTD), closed Wednesday's trading session at $0.04358, down 37.47%, on 3,500 volume with 1 trade. The average volume for the last 3 months is 20,978 and the stock's 52-week low/high is $0.04358/$0.01.


True Leaf Medicine International Ltd. (TRLFF)

Stockhouse,, and MarketWatch reported on True Leaf Medicine International Ltd. (TRLFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

True Leaf Medicine International Ltd., via its wholly-owned subsidiary 'True Leaf Pet, Inc.', has entered the international pet industry with a line of hemp-focused pet supplements in the U.S., Canada, and Europe. The Company’s other subsidiary is ‘True Leaf Medicine, Inc.’. OTCQB-listed, True Leaf Medicine International is headquartered in Vancouver, British Columbia.

True Leaf Pet established in 2015 to pioneer and market hemp-focused products for the pet industry. The Company’s Pet segment markets only legal hemp-seed based pet products online, as well as in stores throughout the U.S., Canada, Europe, and New Zealand.

True Leaf Medicine came on the scene in 2013 to become a licensed producer of medical cannabis. It has received approval from the Government of Canada to construct its facilities.

The Company has filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer of medical cannabis via 'True Leaf Medicine'. True Leaf has passed through the preliminary and enhanced screening process of Health Canada's review.

In late September, True Leaf Medicine International announced that it acquired an option to purchase the 40 acres of land, which encompasses its facility in Lumby, B.C., via its wholly-owned subsidiary True Leaf Medicine, Inc. This Option is exercisable until December 31, 2017. The facility will have a production capacity of greater than 6,000 kilograms of dried cannabis annually. This is once phase one of the project is completed.

Mr. Darcy Bomford, True Leaf Medicine International’s Chief Executive Officer, said, "This is a milestone for True Leaf. This property gives us the capacity to expand to meet the increased demand that is widely expected. With government approvals, the size of this site could allow us to build a 1,000,000 square foot facility and produce more than 125,000 kilograms of cannabis."

This week, True Leaf Medicine International announced that it secured DTC eligibility for its common shares from The Depository Trust Company (DTC) effective October 10, 2017. The DTC is a subsidiary of the Depository Trust & Clearing Corporation (DTCC). The DTC manages the electronic clearing and settlement for the bulk of publicly traded equities and other securities in the United States.

True Leaf Medicine International Ltd. (TRLFF), closed Wednesday's trading session at $0.317, up 2.46%, on 29,071 volume with 16 trades. The average volume for the last 3 months is 67,345 and the stock's 52-week low/high is $0.294/$1.524.


Monarques Gold Corporation (MRQRF)

Barchart, Junior Mining Network, The National Investor, Stockhouse, 4-Traders, Mining & Energy, and YCharts reported on Monarques Gold Corporation (MRQRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 2011, Monarques Gold Corporation is an emerging gold producer headquartered in Montreal, Quebec. Its focus is on pursuing growth via its large portfolio of high-quality projects in the Abitibi mining camp in Quebec. The Company previously went by the name Monarques Resources, Inc. It changed its name to Monarques Gold Corporation in January of 2015. Monarques Gold’s shares trade on the OTC Markets Group’s OTCQB.

Monarques Gold owns almost 300 km² of gold properties. These include the Beaufor Mine, the Croinor Gold, Wasamac, McKenzie Break and Swanson advanced projects. The Company also owns the Camflo and Beacon mills, and six promising exploration projects. Furthermore, Monarques Gold offers custom milling services out of its 1,600 tonne-per-day Camflo mill.

The Beaufor Mine had production of 5,444 ounces of gold in Q2 2018. This represents an increase of 61 percent since its acquisition from Richmont Mines. Annual production at Beaufor is +20K ounces. The Beaufor Mine has strong drilling results, including 61.48 g/t Au over 3.9 m. There is excellent potential to increase the resource at Beaufor.

Last week, Monarques Gold reported new results that mark the end of the Company’s 2017 drilling program at the Beaufor Mine. The results are from a total of 7,157 meters of drilling in 52 holes. This includes 5 exploration holes (2,651 meters) and 47 definition drill holes (4,506 meters). The holes were drilled in multiple areas of the mine, including zone Q, QH2 and 32 and the 350H, 1700 and Granodiorite East projects.

Today, Monarques Gold announced that it has retained BBA to conduct a conceptual study for the transportation of gold-bearing material from the Wasamac deposit to an existing processing plant with an authorized tailings management facility in the area for custom milling. Since acquiring the Wasamac Gold project from Richmont Mines, the Company’s management has been working towards unlocking the considerable potential value of the project.

The first phase of this study will establish an inventory of the primary mining and processing sites in operation and accessible by road and/or rail in the Abitibi region, in Ontario and Quebec, with their locations and qualifications.

The second phase will develop a concept for the transportation of mineralization and/or treatment sludge for the three best options chosen from the sites identified in the prior phase. The principal objective of this phase is to design a concept for transporting the mineralization from the Wasamac deposit to a regional processing plant and tailings facility for custom milling.

Monarques Gold Corporation (MRQRF), closed Wednesday's trading session at $0.178, down 3.26%, on 8,012 volume with 8 trades. The average volume for the last 3 months is 21,854 and the stock's 52-week low/high is $0.1084/$0.349.


Sunvalley Solar, Inc. (SSOL)

Wallstreetlivechat, PennyStockPros, The Stock Scout, Penny Stock Rumble,, PennyStockClub, OurHotStockPicks, PennyStocks24, Fast Moving Stocks, VIP STOCK ALERTS, and FeedBlitz reported previously on Sunvalley Solar, Inc. (SSOL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Sunvalley Solar, Inc., by way of its subsidiary, Sunvalley Solar Tech, Inc., operates as a solar power technology and system integration company in the State of California. The Company centers on solar systems design and installation, solar technology research and development (R&D), and solar equipment manufacturing and distribution areas. Established in 2007, Sunvalley Solar is headquartered in in Walnut, California.

Sunvalley Solar acquired Rayco Energy, Inc. in 2016. Rayco Energy is an established northern California company. It specializes in providing cost-saving and efficient energy solutions to local communities and business units. This includes LED lighting, Solar Thermal, as well as Solar Electricity.

Rayco Energy combines energy efficiency measures with renewable energy sources. It services the multi-family sector (Apartments, Homeowner Associations (HOA)) and small-sized commercial projects.

Sunvalley Solar’s business development strategy is to develop the Company as the end-to-end solar energy solution provider for solar power equipment dealers, solar power system installers, and solar power energy end users.

The Company provides turnkey solar system solutions. These include designing, building, operating, monitoring, and maintaining solar power systems for owners, builders, and architecture firms. Its R&D team comprises PhDs in Optoelectronics. The team specializes in photovoltaic panel technologies (coating and focusing).

In addition, the Company’s focus is in the area of National Solar Technical Support and a Service Center. Sunvalley Solar serves small private residences and large commercial solar power users.

The Company’s R&D team’s projects include 975 kW commercial solar power systems for distribution warehouses and manufacturing companies. Furthermore, projects include 1 MW commercial solar power systems for agriculture farms and cold storage facilities.

Its R&D is presently focusing on developing new coating technology to increase the efficiency of PV panels; developing new focusing technology to reduce the size of silicon cells and reduce the silicon cost per watt; developing solar PV application technology to decrease system level cost; and developing new solar parts – Micro-inverters.

Sunvalley Solar has its patented technology – Networked Solar Panels and Related Methods. It has patented the technology "Networked Solar Panels and Related Methods" (USPTO 12/198,076). This technology enables the solar power system operator to monitor the grid status, and manage and control the output from each panel, each subsystem, and the system as a whole.

Sunvalley Solar, Inc. (SSOL), closed Wednesday's trading session at $0.0379, up 45.77%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 3,004 and the stock's 52-week low/high is $0.0206/$0.079.


Right On Brands, Inc. (RTON), SmallCapVoice, InvestorsHub, MarketWatch, OTC Markets, Barchart, Stockhouse, Capital Cube, Investors Hangout, YCharts, and Investors News Magazine reported on Right On Brands, Inc. (RTON), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Right On Brands, Inc. is a consumer goods company listed on the OTC Markets Group’s OTCQB. The Company specializes in the brand development of health conscious, hemp-infused food and beverage products. Right On Brands comprises three subsidiaries. These are Humbly Hemp, Endo Brands, and Humble Water Company. Right On Brands is headquartered in Los Angeles, California.

The Company is developing, marketing, and investing in industrial hemp, cannabis, adaptogenic superfoods and natural water for a new generation of health-conscious consumers. These products are becoming a part of the daily lives of millions.

Humbly Hemp is a product line of hemp-based products. Each Humbly Hemp bar is kosher, vegan, soy free, dairy free, and gluten-free. They are also free of all top 11 allergens. The basis of the Company’s protein bars are with gluten free rolled oats, hemp seeds, and plant protein.

Endo Water is pH balanced and micro-clustered for antioxidant protection. Additionally, it is oxygenated for improved performance and energy. Endo Water is available in Berry Acai, Lemon Lime, Cucumber, and Watermelon flavors.

Endo Water is infused with a 99.5 percent pure CBD oil, processed employing Nano Technology. This makes the particles one-millionth of its normal size. This process allows the Nano-Sized CBD's to immediately penetrate one’s cells versus the lengthy process of being absorbed by the body's digestive system.

Right On Brands’ Humble Water Company product is a natural spring water sourced from an ancient ice age aquifer at the foothills of the Rocky Mountains situated at the only triple watershed in North America. Humble Water is high in natural alkalinity and it is pure.

This past December, Right On Brands announced that Medical Biochemist Dr. Ashok Patel was appointed Director of Product Development. His expertise is in natural oils and extracts.

This will permit Right On Brands to develop first of its kind, healthy hemp products to be marketed under the Humbly Hemp and Endo Brands. Dr. Patel uses his expertise in medical biochemistry to formulate products, which are safe and effective and provide the benefits of the latest innovations in science.

Also in December, Right On Brands announced the introduction of the above-mentioned Endo Water. This is the first offering of a premium CBD product line to be marketed by the Company.

All of the future CBD offerings will be a part of the Endo Brands family of products. Endo Brands is the wholly-owned subsidiary of Right On Brands. The initial shipment of product was received by Right On Brands. Moreover, an aggressive launch in Southern California is planned for early 2018.     

Right On Brands, Inc. (RTON), closed Wednesday's trading session at $0.05465, down 2.69%, on 394,556 volume with 39 trades. The average volume for the last 3 months is 108,212 and the stock's 52-week low/high is $0.036/$0.65.


Nu-Med Plus, Inc. (NUMD)

Stockhouse, VentureLine, Stockopedia, Business Insider, Morningstar, GuruFocus, Capital Cube, OTC Markets, Marketwired, Investing News, Street Insider, The StreetWise Reports, MarketWatch, The Street, last10k, TradingView, Wallmine, Stockwatch, and Wallet Investor reported previously on Nu-Med Plus, Inc. (NUMD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Nu-Med Plus, Inc. investigates and develops applications of Nitric Oxide technologies in the medical field. The Company established to explore medical applications of newly developed technologies. Its business strategy is to concentrate on high growth potential markets where there is a clearly defined need recognized by the medical community, which can be addressed by Nu-Med Plus and its technical expertise. A medical device enterprise, the Company is based in Salt Lake City, Utah.

Inhaled Nitric Oxide (INO) is a medically essential gas. It is now used in Neonate Hypoxia therapy (inadequate oxygen level in newborns), COPD and other pulmonary problems. Nu-Med has the capability to deliver high purity Inhaled Nitric Oxide (INO) to the patient at point of use. INO may have future applications for an array of other diseases and medical complications that are presently being investigated.

The Company’s markets include neonatal complications, COPD, Tuberculosis, Malaria, and ARDS (a severe lung syndrome with no known cure). Nu-Med’s team has developed a new Nitric Oxide (NO) gas delivery system. This system provides a continuous intra-breath concentration of therapeutic NO to medically supervised patients who are on ventilators in a hospital setting.

In June 2018, Nu-Med Plus announced its patent filing for its leading-edge chemically reactive coating. The coating ensures that only a contaminant free nitric oxide, a life saving drug for neonates, reaches the patient. Nu-Med has developed a unique method for a reactive coating that chemically bonds or adheres to the inside surface of common medical gas delivery tubing. Essentially, the coating removes toxic contaminants that are found in nitric oxide delivery systems.

Last month, Nu-Med Plus announced a patent application on a new device designed to pretreat stored blood products with nitric oxide before patient transfusions. The Company’s patent describes the new technology as a simple nitric oxide infusion device, which can be used during or post blood collection.

With this new device, Nu-Med Plus will now seek enrollment in further studies to investigate its efficacy. At present, the Company is in the process of Food and Drug Administration (FDA) approval for three additional nitric oxide delivery units. These include a fixed hospital unit, a clinical unit, as well as a portable unit.

Nu-Med Plus, Inc. (NUMD), closed Wednesday's trading session at $0.85, even for the day. The average volume for the last 3 months is 971 and the stock's 52-week low/high is $0.30/$1.01.


theMaven, Inc. (MVEN)

InvestorsHub and Stockhouse reported on theMaven, Inc. (MVEN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, theMaven, Inc. is an expert-driven, group media network. The Company’s advanced platform serves, by invitation-only, an alliance of professional, independent channel partners. theMaven’s Executive team and operational Board members include digital media pioneers Mr. James Heckman and Mr. Ross Levinsohn, as well as technology innovators Mr. Bill Sornsin and Mr. Ben Joldersma. A digital media start-up, theMaven has its head office in Seattle, Washington.

The Company provides elite content leaders an end-to-end digital platform within a cooperative that shares resources and distribution and maximizes monetization. theMaven enables partners to concentrate on the vital drivers of their businesses - creating, informing, sharing, discovering, leading, and interacting with the communities and constituencies they serve.

theMaven enables partners to do so through providing wider distribution, more community engagement, and efficient advertising and membership programs. During Q2 2017, theMaven focused on three key strategic initiatives - developing its technology platform, business development to sign new Mavens to its network, and launching operations with certain Mavens.

On January 5, 2018, Maven announced that it agreed to acquire HubPages in a union that will bring together over 40 million monthly unique users together in a single premium digital media network, the two companies announced after signing a letter of intent (LOI). The expectation is that this transaction will close within 90 days.

HubPages’ network will undergo migration to Maven’s publishing and community platform, relaunched as part of a single premium network, on one platform for advertisers. The expectation is that moving the network to Maven will improve traffic, engagement, as well as monetization.

Migration of the 27 premium channels to Maven’s platform will happen one at a time, over the next year, subsequent to testing and developing the migration plan. HubPages will remain a vital “cultivating” network, at

At the end of January, Maven announced it is partnering with to provide Maven’s content creators protection from improper use of their content and ensure fair monetization. is a blockchain-based open universal ledger for digital creative assets.

Using cryptography, gives content creators and publishers the tools to automate the licensing process without relying on third parties. will provide Maven publishers with the ability to timestamp and validate their content and digital assets in an unchangeable system that will automatically issue digital ownership certificates.

This month, Maven announced that Mr. Josh Jacobs, former Omnicom and Yahoo! senior executive, was named President and Executive Chairman of Maven after joining originally as a consultant and serving as Maven’s Co-Chair over the last year. Mr. Jacobs is an innovator in digital advertising, on the demand and supply sides, and a major media veteran with senior executive roles at Glam, Yahoo!, as well as Omnicom.

theMaven, Inc. (MVEN), closed Wednesday's trading session at $0.35, up 23.96%, on 12,763 volume with 7 trades. The average volume for the last 3 months is 13,709 and the stock's 52-week low/high is $0.25/$2.57.


Abtech Holdings, Inc. (ABHD)

Greenbackers, Zacks, Morningstar, InvestorsHub, MarketWatch, Stockwatch, Stealth Stocks, Wyatt Investment Research, Investor Ideas, Stock Mister, OTC Journal, The Stock Psycho, Wall Street Resources, Equity Clock, GuruFocus, Wallet Investor, FeedBlitz, Topgun stockpicks, Hidden Values Alert, CoolPennyStocks, AllPennyStocks, Stockhouse, and Stockopedia reported previously on Abtech Holdings, Inc. (ABHD), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Abtech Holdings, Inc. is a full-service environmental technologies and engineering company. It provides creative solutions to communities, industry, and governments addressing issues of water pollution and contamination. The OTCQB-listed Company provides solutions for Stormwater Management, Oil & Gas Water Treatment, and Industrial Water Treatment. Abtech Holdings is headquartered in Scottsdale, Arizona. AbTech Industries, Inc. is a subsidiary of Abtech Holdings.

In 2012, Abtech commenced marketing of produced water and industrial wastewater treatment and formed its engineering subsidiary AEWS Engineering. AEWS is an independent civil and environmental engineering firm partnered with leading research and engineering universities.

The basis of Abtech’s products is on polymer technologies that can remove hydrocarbons, sediment, and other foreign elements in stormwater runoff, flowing water, and industrial process and wastewater. The Company’s products include advanced filtration media technologies and diverse water treatment systems.

Abtech’s offerings include the antimicrobial technology- Smart Sponge® Plus. This technology is effective in decreasing coliform bacteria found in stormwater, industrial wastewater, and municipal wastewater. Smart Sponge® Plus is registered with the Environmental Protection Agency (EPA).

Abtech has installed and validated onsite its first mobile water pre-treatment system focused on oil recovery and hydrocarbon removal for the treatment of flowback and produced water for the on-shore Oil & Gas industry. This pre-treatment system integrates its Smart Sponge® technology. The design of it is to operate in advance of other treatment systems, increasing overall efficiency and reducing treatment expense.

This past September, Abtech Holdings reported that its subsidiary, AbTech Industries accepted a $318,240 order from Hugo Neu Corporation, a related party, for the installation of four stormwater outfall pipes at the Kearny Point Industrial Park redevelopment project in northern New Jersey. As disclosed in Abtech's 2018 Proxy Statement, Hugo Neu Corporation is a "related party" because it has a beneficial ownership interest in Abtech of roughly 13 percent.

Kearny Point Industrial Park is a 130-acre industrial campus in South Kearny, New Jersey located at the convergence of the Hackensack and Passaic Rivers, adjacent to Newark Liberty International Airport and the Port of Newark. Before receiving this order for end of pipe product applications, AbTech fulfilled a $27,000 order for its Ultra-Urban® filters that were installed in 17 drains on this site earlier in 2018.

Abtech Holdings, Inc. (ABHD), closed Wednesday's trading session at $1.00, even for the day, on 5,269 volume with 5 trades. The average volume for the last 3 months is 15,643 and the stock's 52-week low/high is $0.51/$3.70.


CleanSpark, Inc. (CLSK)

Stockrow, Financial Content, WalletInvestor, Investor Place, Penny Stock Tweets, Investors Hangout, Street Insider, OTC Markets, InvestorsHub, Stockhouse, The Street, Market Exclusive, 4-Traders, Stock News Now, and Momentus News reported earlier on CleanSpark, Inc. (CLSK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CleanSpark, Inc. is a microgrid company with advanced engineering, software and controls for innovative distributed energy resource management systems. The Company provides advanced energy software and control technology, which enables a plug-and-play enterprise solution to modern energy challenges. The Company previously went by the name Stratean, Inc. It changed its corporate name to CleanSpark, Inc. in November 2016. CleanSpark’s shares trade on the OTC Markets’ OTCQB.

CleanSpark’s services consist of intelligent solar monitoring solutions, microgrid design and engineering, project development consulting services, system installation and consulting, and turn-key microgrid implementation services. Additionally, the Company combines its microgrid services with a leading-edge and patented stratified downdraft gasifier.

CleanSpark’s products include DNAPOWERPLAN™, Turnkey Microgrid Development Services, and mPULSE GRID MANAGEMENT™. Its PowerPlan shows owners, tenants and stakeholders how to use energy generation, storage and advanced automation to achieve 25, 50 or even 100 percent grid independence.

Regarding Turnkey Microgrid Development Services, CleanSpark develops, constructs, installs and maintains income producing nano and microgrids. CleanSpark helps customers make money through developing their own energy assets.

Concerning mPULSE GRID MANAGEMENT™, the Company’s mPulse software and controls package collects, archives, as well as analyzes data 24/7. This provides real-time control and reporting. It ensures that a customer’s projects are performing according to the DNA PowerPlan. Through advanced monitoring, predictive analytics and professional maintenance, CleanSpark ensures optimal performance of a customer’s microgrid and maximum revenue.

CleanSpark executed an agreement for an $18.3 million 'Zero Net Energy' Microgrid with an S&P 500 Member Real Estate Investment Trust (REIT). This agreement calls for CleanSpark to provide engineering, design, and consultation services and follow-on construction work to install a Microgrid designed by its engineering team and employing its mVSO software in creating the system design. The completed system will be operated by CleanSpark's patented mPulse enterprise controller. Project completion is planned for mid-2019.

CleanSpark is nearing construction completion on its $900,000 contract with Bethel-Webcor JV to install a 'turn-key advanced microgrid system' at the U.S. Marine Corps Base Camp Pendleton. This contract has been in direct support of the United States Department of Navy's communication information system (CIS) operations complex. CleanSpark has performed as a sub-contractor to the JV for the design and construction of the microgrid spanning numerous facilities with inter-connectivity at the U.S. Marine Corps Base Camp Pendleton project P-1132.

CleanSpark, Inc. (CLSK), closed Wednesday's trading session at $3.08, up 26.75%, on 206,726 volume with 403 trades. The average volume for the last 3 months is 36,783 and the stock's 52-week low/high is $0.89/$15.01.


TimefireVR, Inc. (TFVR)

Barchart, Stockhouse, Marketwired, InvestorsHub, MarketWatch, and Street Register reported on TimefireVR, Inc. (TFVR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

TimefireVR, Inc. is a software company with a virtual reality platform for immersive, interactive, as well as social experiential learning. The Company formed in early 2014 to develop a virtual reality application platform, Hypatia, built on pillars of social interaction, commerce, cultural immersion, and entertainment. Hypatia is a curated virtual reality destination metaverse of massive scale.

On September 14, 2016, EnergyTek Corp. announced that it merged with Timefire LLC. The Company subsequently changed its name to TimefireVR, Inc. A technology enterprise, TimefireVR is headquartered in Scottsdale, Arizona.

Hypatia is influenced from some of the most visited cities in the world. TimefireVR's VR platform application provides an environment for cooperative participation and experiential learning in a safe environment.

With Hypatia, one can socialize, talking via text or audio. One can also shop; watch videos, concerts, and plays. With Hypatia, a user can create and customize the world about them. Additionally, a user can travel to real cities and fantasy destinations.

In June of 2017, TimefireVR formally launched its exclusive Virtual Reality title Hypatia, its multi-player multi-hour social environment.

However, last month, TimefireVR announced shifting its main corporate emphasis towards the strategic investments in crypto currency and potential acquisitions of blockchain technology businesses. As part of the shift in strategic direction, it sold its virtual reality assets. In addition, it appointed Mr. Jonathan Read to serve as Chief Executive Officer (CEO), Secretary, and Treasurer of TimefireVR.

Mr. Read has been a Director of TimefireVR since August 18, 2017. Since July 14, 2017, he has served as a member of the Board of Directors of BTCS, Inc. (BTCS), a blockchain technology focused company.

Mr. Jonathan Read, TimefireVR’s CEO, said, “Blockchain technology and its application of crypto currencies is an amazing enabling technology paradigm that will have a profound and disruptive impact on a host of industries. I am incredibly proud of our accomplishments in virtual reality; however, the Board of Directors made a strategic decision, in the best interest of our shareholders, to leverage my experience in blockchain technology where I serve as a member of the Board of Directors of BTCS Inc. (OTC Pink:BTCS), our strategic business vision and our ability to access the capital markets immediately.”

TimefireVR announced the sale of its virtual reality assets, mainly the social media/education platform and virtual world “Hypatia” to a group of investors. This includes its original founders, Mr. John Wise and Mr. Jeffrey Rassas. The expectation is that Hypatia will be a VR destination content leader. Consistent with this sale, TimefireVR expects to change its name following Board and shareholder approval.

At first, TimefireVR will concentrate on Ethereum, which is a foremost blockchain platform for Decentralized Applications (DApps). These are applications that run on a peer-to-peer network of computers instead of on one single computer or server.  

TimefireVR, Inc. (TFVR), closed Wednesday's trading session at $0.0017, down 32.00%, on 160,419 volume with 9 trades. The average volume for the last 3 months is 397,398 and the stock's 52-week low/high is $0.0017/$0.185.


MPX Bioceutical Corporation (MPXEF)

Jet Life Penny Stocks, Stockwatch, Investorx, 4-Traders, TradingView, OTC Markets, OTC Dynamics, TalkMarkets, Barchart, Penny Stock Hub, Stockhouse, MarketWatch, InvestorsHub, Investing News Alerts, and High Rising Stocks reported earlier on MPX Bioceutical Corporation (MPXEF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

MPX Bioceutical Corporation, by way of its wholly-owned subsidiaries in the U.S., provides management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis businesses in Arizona. These businesses operate under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. With the acquisition of The Holistic Center, MPX added another operating medical cannabis enterprise to its position in Arizona.

The Company formerly went by the name The Canadian Bioceutical Corporation. It changed its name to MPX Bioceutical Corporation in November of 2017. The Company is based in Toronto, Ontario and lists on the OTCQX.

In addition, MPX Bioceutical has operations in Massachusetts. In Massachusetts, MPX is building out and will operate a cultivation and production facility and up to three dispensaries. It also manages three full service dispensaries and one producer in Maryland.

MPX Bioceutical has operations centered in the U.S. in the adult use and medical cannabis markets. It has completed its agreement to acquire GreenMart operations in Nevada. In Canada, MPX acquired Canveda that has received its cultivation license from Health Canada. It will operate a cultivation and production facility in Peterborough, Ontario. Additionally, the Company leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. MPX will also continue its efforts to develop its legacy nutraceuticals business.

Pertaining to Pharma-grade products, MPX signed a definitive agreement to establish a joint venture (JV) with Panaxia. This JV is to develop proprietary, smokeless pharma-grade products using cannabis.

Moreover, MPX has entered into a definitive agreement with Panaxia Pharmaceutical Industries Ltd. Panaxia is an Israeli company. It engages in the business of development and production of pharma grade cannabidiol medicinal products, medicinal preparations, and medicinal accessories through MPX’s wholly-owned subsidiary Salus BioPharma Corporation.

Recently, MPX Bioceutical announced that it will open a new Health for Life dispensary in Nottingham, Maryland that is located at 4741 Ridge Rd, Nottingham, Maryland, 21236. This dispensary is operated by the Company’s indirect wholly-owned subsidiary, S8 Management LLC, via a management agreement with LMS Wellness, Benefit LLC that provides all management services usually required by a dispensary facility to successfully operate. This is MPX’s third dispensary in Maryland, following the opening of its flagship Health for Life dispensary in Bethesda, in August of this year and Health for Life dispensary in Baltimore, in October 2018.

This week, MPX Bioceutical announced that GreenMart NLV, LLC, a subsidiary of the Company, was awarded four conditional retail marijuana store licenses in Nevada. The jurisdictions granted by the State include The City of Las Vegas, Unincorporated Clark County, Reno, and Henderson. GreenMart NLV is a fully-operational cultivation, production and kitchen facility, which produces MPX-branded wholesale products for the adult-use and medical markets in Nevada. The new dispensaries will operate under the “Health for Life” brand. This is MPX’s flagship retail brand.

MPX Bioceutical Corporation (MPXEF), closed Wednesday's trading session at $0.69, down 2.82%, on 500,000 volume with 401 trades. The average volume for the last 3 months is 1,547,269 and the stock's 52-week low/high is $0.30/$0.97.


Protalex, Inc. (PRTX)

StreetInsider, Zacks, TopStockAnalysts, and OTCPicks reported on Protalex, Inc. (PRTX), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Protalex, Inc. is a clinical-stage Biopharmaceutical Company based in Florham Park, New Jersey. Its emphasis is on the development of a class of drugs for treating autoimmune and inflammatory diseases. These include RA (Rheumatoid Arthritis) and ITP (Immune Thrombocytopenia). The Company’s lead product is PRTX-100. This is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. Protalex’s shares trade on the OTC Markets Group’s OTCQB.

Rheumatoid arthritis (RA) is an autoimmune disease. RA is a disorder in which the body’s immune system mistakenly attacks the joints. Immune Thrombocytopenia (ITP) is a blood disorder. ITP can result in easy or excessive bleeding and bruising because of the body’s inability to form blood clots.

Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP through reducing the immune-mediated destruction of the platelets. Protalex has open IND’s for the treatment of RA and ITP in the United States, and in Europe, an open IMPD for ITP.

Protalex’s PRTX-100 can (at very low concentrations) bind to human B-lymphocytes and macrophages and to modulate immune processes. PRTX-100 has been granted Orphan Drug Designation in the United States and in Europe for the treatment of ITP. This status provides commercial exclusivity benefits, tax credits for certain research, potential research grants and a waiver of the New Drug Application user fee in the United States. Currently, it is the subject of clinical studies in the U.S. and Europe.

PRTX-100 is administered as a short intravenous infusion. The following patents have been granted for PRTX-100: U.S. Patent No. 9,370,552 (‘552 patent) is a continuation patent to initial U.S. patent No. 7,211,258 (Protein A compositions and methods of use) filed in 2002 and issued with method of treatment claims for RA, juvenile RA, and systemic lupus erythematosus (SLE). The ‘552 patent expands the method of treatment of PRTX-100 to include type 1 diabetes.

European Patents No. 2,570,136 and 2,206,511 (national patents in place in France, Germany, Italy, Spain, Switzerland, and the UK) includes composition claims relating to numerous autoimmune diseases (RA, ITP, juvenile RA, psoriasis, myasthenia gravis) and dosage expansion.

Canadian patents No. 2,894,098 and No. 2,481,282 comprise method of treatment claims relating to RA and SLE. Japanese patent No. 5,523,796 claims compositions for treating psoriasis, scleroderma, Crohn’s Disease, myasthenia gravis, ulcerative colitis, psoriatic arthritis, as well as pemphigus vulgaris.

Recently, Protalex announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRTX-100-203 Study) in adults with persistent/chronic Immune Thrombocytopenia (ITP), it initiated enrollment in the fifth and highest dose cohort of this dose-escalating study.

The first patient in the final cohort was recently dosed in the United Kingdom at 24 micrograms/kg. This the highest dose of PRTX-100 used in any clinical trial to date. One of the three patients treated in the fourth dose cohort (18 micrograms/kg) attained a protocol defined platelet response.

Protalex, Inc. (PRTX), closed Wednesday's trading session at $0.10, up 53.85%, on 11,700 volume with 4 trades. The average volume for the last 3 months is 3,525 and the stock's 52-week low/high is $0.065/$0.89.


Grom Social Enterprises, Inc. (GRMM)

Wall Street Analyzer, InvestorsHub, New Media Wire, Business Insider, last10k, Street Insider, Canadian Insider, Stockopedia, TradingView, Barchart, Wallet Investor, YCharts, Stockhouse, Marketwired, Insider Tracking, and Dividend Investor reported on Grom Social Enterprises, Inc.. (GRMM), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Grom Social Enterprises, Inc. wholly owns various separate subsidiaries. This includes Grom Social, which is a safe social media platform for children between the ages of five and 16. Grom Social has attracted children and parents with the promise of a safe and secure environment where their children can be entertained and can interact with their peers while learning proper digital citizenship. OTCQB-listed, Grom Social Enterprises is based in Boca Raton, Florida.

With Grom Social, children can create a profile; make friends, talk, and share content. Grom is a social community with a wide array of original content and engaging features. These include exclusive Grom TV videos, fun Grom games, interesting photos, and thought provoking Fan Pages. Inappropriate content or behavior on Grom Social is identified by digital filters and the Company’s cast of Grom Helpers. Grom Helpers are real people who monitor the website 24 hours a day, 7 days a week, 365 days a year.

Grom Social has its Parent Portal - a tool available to parents and guardians. The Parent Portal allows them to monitor and control all of their child’s activity on Grom Social. Parents can set privacy settings; examine chat histories; and review and control who their child is friends with.

Grom Social Enterprises also owns and operates Top Draw Animation, Inc. This is an award-winning animation enterprise. Top Draw Animation produces animated content for Grom Social and other high-profile media properties.

Grom Social Enterprises’ subsidiary, Grom Educational Services (GES), opened a new 1,400 square foot office in Norcross, Georgia on January 1, 2018. This is to house the Company’s NetSpective WebFilter division. NetSpective WebFilter provides protection and security for schools and students meeting and surpassing CIPA requirements for technology protection measures and internet safety policies that include filtering and monitoring the online activities of minors/students.

Furthermore, Grom has its MamaBear Mobile/Desktop Application. MamaBear is the inventive, mobile, all-in one parenting app. It creates a private family communication hub. Families communicate, locate, organize, and also protect their children with peace of mind. Also, the Company’s Grom Nutritional Services has its Just Brilliant offering. This is a nutritional supplement formulated to provide dietary supplementation of selected nutrients.

Last month, Grom Social Enterprises announced that it entered into a strategic partnership agreement with Child Rescue Coalition (CRC). CRC is a non-profit organization centered on utilizing proprietary technology to protect children against predators. This partnership adds an additional layer of security to Grom Social’s already secure and safe kids’ social network through flagging and filtering out IP addresses that may be of concern.

This partnership aligns and strengthens two of the most active online child safety advocates in the U.S. As both of these public-private industry influencers unite, it will ensure Grom Social can continue to provide an extremely safe environment for children to navigate the Internet. With this agreement, the parties agree to work together to enhance Grom Social’s Trust and Safety protocols on its website employing CRC’s proprietary IP monitoring technology.

Grom Social Enterprises, Inc. (GRMM), closed Wednesday's trading session at $0.29, up 3.57%, on 5,500 volume with 3 trades. The average volume for the last 3 months is 12,012 and the stock's 52-week low/high is $0.10/$0.96.


Thunder Mountain Gold, Inc. (THMG)

Streetwise Reports, FeedBlitz, Zacks, Marketbeat, Silicon Investor, Simply Wall St, The Street, Wallet Investor, 24hgold, Morningstar, MarketWatch, Business Wire, Pink Investing, and GuruFocus reported on Thunder Mountain Gold, Inc. (THMG), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Thunder Mountain Gold, Inc. is a junior gold exploration company headquartered in Boise, Idaho. It owns interests in numerous U.S. precious metals projects. The Company’s chief asset is The South Mountain Project. The South Mountain Project is on private and patented land in southern Idaho, just north of the Nevada border. Established in 1935, Thunder Mountain Gold lists on the OTC Markets Group’s OTCQB.

Thunder Mountain Gold owns 100 percent of the South Mountain Mine. This mine has a land package consisting of approximately1,200 acres of mostly private land - both owned outright and leased. A new gold discovery was revealed during fieldwork at South Mountain in 2009. The Company’s plan of operation for this, subject to business conditions, is to continue to advance the development at the South Mountain Project.

The primary metals at South Mountain are silver, zinc, lead, copper, and gold. The flagship South Mountain Project remains Thunder Mountain Gold’s focus.

In addition, Thunder Mountain Gold has its Trout Creek Project. The Trout Creek target is in the Reese River Valley area south of Battle Mountain, Lander County, Nevada. This is a grass roots gold target in the Eureka-Battle Mountain trend of central Nevada, now under Joint Exploration Agreement with Newmont USA Limited. This target consists of 60 unpatented lode mining claims.

Thunder Mountain Gold’s other projects include Clover Mountain. The Company controls 40 unpatented lode mining claims covering about 800 acres, near Clover Mountain in Owyhee County, Idaho. Moreover, the Company’s West Tonopah Property comprises 8 unpatented lode mining claims totaling 160 acres in the Tonopah Mining District, Esmeralda County, Nevada.

Thunder Mountain Gold announced in June 2018 that it filed a new National Instrument 43-101 (NI 43-101) Technical Report that included a new mineral resource estimate on the South Mountain Project. The Technical Report has an effective date of April 7, 2018.

Hard Rock Consulting, LLC (HRC) of Lakewood, Colorado completed the Technical Report for the South Mountain Project. HRC concluded that significant potential exists to boost the known mineral resource with additional drilling, and to upgrade existing mineral resource classifications with additional infill drilling. The most recent Thunder Mountain Gold drilling program was successful in defining the geometry and confirming the grades of the DMEA and Texas massive sulfide zones.

In 2007, South Mountain Claim Group was purchased by Thunder Mountain Gold from a private landowner. The flagship property was first mined in the late 1800s. Mineralization consists of skarn-hosted polymetallic sulfide ore bodies hosted in a Paleozoic and/or Mesozoic carbonate unit. The property was mined underground extensively during World War II.

Thunder Mountain Gold, Inc. (THMG), closed Wednesday's trading session at $0.089, even for the day. The average volume for the last 3 months is 3,274 and the stock's 52-week low/high is $0.035/$0.219.


The QualityStocks Company Corner

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures, Inc. (OTC:NUGS), today announced a major common share restructuring led by Chief Executive Officer, Simon Yu, who will cancel 60 million shares as part of the Company’s efforts to increase shareholder value and to uplist on the OTCQB Venture Market Place.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $2.52, up 18.87%, on 113,958 volume with 300 trades. The average volume for the last 3 months is 49,025 and the stock's 52-week low/high is $0.058/$7.13.

Recent News

chart (CIIX)

The QualityStocks Daily Newsletter would like to spotlight (CIIX)., Inc.’s (OTCQB: CIIX) LOI with BCDBG, Inc. for the global Asian community sales rights to organic VitaMist is not only expected to expand its consumer division; it also calls for development of an exclusive line giving CIIX vitamin spray as well as a vitamin/CBD spray technology. The result would be the growth of CBD products internationally for CIIX ( Also today, CannabisNewsWire released a report highlighting the company which examines the recent news that the government of New Zealand passed the medical cannabis bill earlier today (December 11). The bill provides a legal defense to anyone prosecuted for consuming medical cannabis during the time when a scheme has not yet been established to regulate how medical cannabis can be accessed.

Founded in 1999, (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. (CIIX), closed the day's trading session at $0.59, up 3.51%, on 87,042 volume with 71 trades. The average volume for the last 3 months is 530,761 and the stock's 52-week low/high is $0.365/$1.58.

Recent News


Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF), is pleased to announce that the Company has completed the commissioning process for its prototype crystallisation pilot plant and has produced its first quantity of high purity (>99.1%) lithium carbonate.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.


Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $0.739, up 1.37%, on 41,610 volume with 39 trades. The average volume for the last 3 months is 48,788 and the stock's 52-week low/high is $0.604/$2.09.

Recent News


CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that its board of directors has appointed Scott A. Kelly, M.D., FAAPMR as chairman of the board.  Dr. Kelly has served as a member of CytoDyn’s board since April 2017 and succeeds Anthony D. Caracciolo, who will continue to serve as a director of the Company.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.54, even for the day, on 248,199 volume with 71 trades. The average volume for the last 3 months is 200,057 and the stock's 52-week low/high is $0.40/$0.836.

Recent News


BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

The holidays can be a particularly poignant time for receiving a cancer diagnosis as all of society celebrates a season of cheer and shares goodwill with each other, but the San Antonio Breast Cancer Symposium (SABCS), one of the largest breast cancer conferences in the world, and participants such as BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), shared a gift of knowledge about breast cancer this month through presentations on the latest science in the fight against it and the avenues of hope for those who have been diagnosed with it.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.077, up 1.32%, on 66,000 volume with 3 trades. The average volume for the last 3 months is 18,196 and the stock's 52-week low/high is $0.068/$0.1387.

Recent News


Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA) is pleased to announce that the Company has upgraded its trading tier on the OTC Markets to the OTCQB Venture Marketplace. Also today, the company was highlighted in an article from, which examines how the United States Senate passed the 2018 Farm Bill on Tuesday thus paving the way for CBD and hemp legalization. Additionally, MCOA was featured today in a report by CannabisNewsWire which digs deeper into the overall vectorization. With federal legalization of hemp expected in the United States by Christmas, the farming and cannabidiol product industries are anticipating great changes in their future.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0275, up 58.05%, on 100,219,166 volume with 2,991 trades. The average volume for the last 3 months is 9,788,561 and the stock's 52-week low/high is $0.0115/$0.0728.

Recent News


Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (GOHE) (“Global”) and its wholly owned subsidiary MTrac Tech Corp. (“MTrac” or the “Company”) are pleased to announce that its payment platform is expanding into Washington state and three new markets in California; Los Angeles, Sacramento and the Bay Area. These agreements represent strategic growth into 7 states and a footprint into some of the largest cannabis markets in the country.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.0084, up 15.07%, on 5,352,243 volume with 104 trades. The average volume for the last 3 months is 7,111,447 and the stock's 52-week low/high is $0.0049/$0.131.

Recent News


Icon Exploration Inc. (TSX.V: IEX.H)

The QualityStocks Daily Newsletter would like to spotlight Icon Exploration Inc. (IEX.H).

NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Icon Exploration Inc. (TSX.V: IEX.H), a client of NNW currently focused on assessing potential acquisition targets in the cannabis industry. The interview can be heard at

Icon Exploration Inc.'s (TSX.V: IEX.H) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.


Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

Icon Exploration Inc. (TSX.V: IEX.H), closed the day's trading session at $0.41, even for the day. The stock's 52-week low/high is $0.15/$0.84.

Recent News


Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services (OTCQB: SHRV) this morning provided a recap of its attendance and presentation at last week’s LD Micro’s 11th Annual Main Event. To view the full press release, visit:

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.30, even for the day, on 20 volume with 1 trade. The average volume for the last 3 months is 13,575 and the stock's 52-week low/high is $0.125/$0.59.

Recent News


Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

Redfund Capital Corp (CSE: LOAN) (Frankfurt: O3X4) (OTC: PNNRF) (“Redfund” or the “Company”) announces strategic alliance between Winterlife Inc. and Mary’s Wellness Ltd. to begin global cannabis products launch.

Redfund Capital Corp. (CSE: LOAN) (OTC: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

  • Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
  • Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

  • Diversifying investments in Canada and other countries
  • Building an international footprint with established national leaders
  • Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
  • Introducing companies to Canada as a viable option for public listings
  • Becoming a premier go-to lender for established companies

The company’s revenue sources include:

  • Interest-bearing debt instruments with asset-backed collateral to securitize loans
  • Equity kicker of warrants coverage on original loan
  • Conversion ability of loan in its entirety
  • Advisory fees from contracts for consulting on growth strategies
  • Right of first refusal on future financing in each company funded

Redfund Capital Corp. (PNNRF), closed the day's trading session at $0.279, even for the day. The average volume for the last 3 months is 529 and the stock's 52-week low/high is $0.244/$0.505.

Recent News


Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF)

The QualityStocks Daily Newsletter would like to spotlight Therma Bright, Inc. (OTC: THRBF).

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) was featured today in a report by CannabisNewsWire examining how the midterm elections last month saw a large number of Missouri voters turn out to vote in favor of Amendment 2, the ballot measure which was intended to legalize medical marijuana.

Therma Bright, Inc. (TSX.V: THRM) (OTC: THRBF) is a medical device technology provider focused on addressing dermatological needs in the multi-billion-dollar cosmeceutical industry. The company’s effective, non-invasive and pain-free skin care is based on proprietary technology which has received Class II medical device status from the U.S. Food and Drug Administration.

Therma Bright’s portfolio includes products, devices and treatments that have both cosmetic and medicinal or therapeutic benefits, such as for relief of pain, itch and inflammation resulting from more than 20,000 types of insect and marine life bites and stings, including bees, wasps, hornets, mosquitos, black flies and jellyfish.

The Company’s current focus is to market its products online through various social media networks, and to eventually re-establish relationships with major North American and Global retailers.


The company currently has two products on the market and another in the research and development phase:

InterceptCS™ is a thermal therapy device for the treatment and prevention of cold sores caused by the herpes simplex Type 1 virus*. Symptoms typically include sores around the mouth and lips which InterceptCS™ treats by application of controlled topical heat with no risk of burning the skin. When used at the first sign of an oncoming cold sore application of InterceptCS™ can prevent symptoms from developing. Infrared energy and light from the device penetrate the skin killing cells infected with the virus.

InterceptCS™ is available without prescription and comprises a battery powered ergonomic hand-held unit and a disposable single-use treatment activator. Therma Bright has completed prototyping of multi-use activators for InterceptCS™. The company plans to bring to market 5, 10 or 20 multi-use activations at prices that will offer customers greater value than the current single-use activator.

The other Therma Bright product currently under development is TherOZap™, a next generation thermal therapy device powered by the company’s core technology, which is approved by the FDA as a Class II medical device for the relief of the symptoms of insect bites. Therma Bright is testing a new easier-to-use prototype of the device for effectiveness against Zika virus and other diseases carried by mosquitos. Once the technology proves effective, Therma Bright intends to seek regulatory approvals and extend the prototype enhancements to a new commercial version of TherOZap™.


Therma Bright is also conducting research and development on a unique thermal therapy device that would incorporate medical grade cannabis or cannabidiol (“CDB”) sourced from hemp as a cream or gel to provide relief of back, knee and other joint pain. In preparation, the company has incorporated a wholly owned subsidiary to hold any technology for use or application of cannabis. Once approvals are secured, the company plans to sell the device through licensed cannabis producers or retailers across Canada and in international markets where use of cannabis has been legalized. The company has initiated trademark and patent protection for its thermal therapy technology incorporating medical cannabis. Therma Bright has indicated it will seek an acquisition to help further development of this product.

Market Opportunity

A report by market intelligence firm Mordor Intelligence put the global cosmeceuticals market at a value of nearly US$47 billion in 2017 and projects it to be worth more than $80 billion by 2023, growing at a rate of almost 9.5 percent annually. Medical research estimates that somewhere between 20 percent and 40 percent of the population suffer occasional cold sore outbreaks. In Canada those figures would mean five to 10 million people, and in the U.S. some 40 million to 80 million, with recurring cold sores, representing a substantial potential market for Therma Bright.


Rob Fia serves as Therma Bright chairman and CEO. Fia has extensive contacts in the investment community and the financial sector as well as knowledge of various Canadian stock exchange listing processes and requirements. His 18 years in the investment business has included equity research and advising promising early stage companies on corporate finance. Therma Bright CFO Victor Hugo is a senior financial analyst at Marrelli Support Services Inc., for which he provides CFO, accounting, regulatory compliance, and management advisory services to companies listed on the TSX, TSX Venture Exchange and other Canadian and US exchanges.

**Based on double blind placebo study, the InterceptCS™ is approved by Health Canada for the claim “For prevention of cold sores when used within 3 hours of the onset of the prodrome.” The InterceptCS™ is not approved by the United States FDA or any claim of clinical indication, clinical efficacy, and/or cure or prevention of disease.

Therma Bright, Inc. (OTC: THRBF), closed the day's trading session at $0.029, even for the day. The average volume for the last 3 months is 153 and the stock's 52-week low/high is $0.0256/$0.0289.

Recent News


VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) (“VIVO” or the “Company”) today announced that it has granted, effective today, an aggregate of 2,790,500 stock options (each, an “Option”) to certain directors, officers, employees and consultants of the Company in accordance with the Company’s stock option plan.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.62564, off by 3.75%, on 121,902 volume with 89 trades. The average volume for the last 3 months is 418,641 and the stock's 52-week low/high is $0.5198/$3.293.

Recent News


Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8)

The QualityStocks Daily Newsletter would like to spotlight Kontrol Energy Corp. (CSE: KNR).

In the nine months ended in September 2018, Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8) saw an increase in revenue of 35 percent on an annual basis. The revenue for the first nine months of the year was $6.6 million (in comparison to $4.9 million for the same period of 2017) and the quarterly revenue for Q3 also reached record levels of $2.4 million (in comparison to $2.2 million in September 2017).

Kontrol Energy Corp. (CSE: KNR) (FSE: 1K8) specializes in the integration of smart energy technologies and solutions for North American commercial and industrial property owners and operators to help them benefit from energy cost savings and minimize greenhouse gas emissions. Kontrol is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology and is ranked by Canadian Business and Maclean’s as the 7th fastest growing startup in 2018.

Kontrol’s leadership position is reshaping the way customers use, manage and strategically allocate energy resources to realize immediate energy savings by gaining more control over energy consumption and demand in real-time.

As the fastest growing global “fuel source,” energy efficiency is big business with industry analysts noting this multi-trillion-dollar market offers significant opportunities over the next five years. Established market segments include: energy retrofits ($71.4 billion); distributed generation ($179.9 billion); energy analytics ($33.5 billion); and greenhouse gas/carbon measurement, reduction ($1.2 trillion). Each $1 invested in energy efficiency displaces up to $3 of utility-scale transmission and distribution investment, according to the International Energy Agency.

Formed in 2015 by a group of energy veterans who recognized that the energy efficiency industry is one of the fastest growing fuel sources for the global economy, Kontrol is committed to enhancing and improving its customers sustainability objectives. In less than two years, Kontrol has grown its revenue run rate to $16 million from $1.8 million, delivering on stated goals and objectives as it seeks to continue this pattern through accretive acquisitions and the expansion of the company’s smart energy technologies.

Up to 50 percent of Kontrol’s overall revenues are recurring annually, and the company’s 2019 outlook includes strategic initiatives that will expand the company’s smart energy technologies to U.S. markets, bring additional accretive and strategic acquisitions, and accelerate recurring SaaS revenues.

Kontrol’s strategy of disciplined mergers and acquisitions includes the following highlights:

  • Acquisition of Log-One Ltd.’s award-winning energy conservation technology, Energy Management System (“EMS”), an intelligent, occupancy-based heating and air-conditioning control system for commercial and multi-residential real estate. Rebranded as Kontrol EMS Technology, the company has added IoT and mobile application capabilities, creating a recurring revenue platform through a Software-as-a-Service (SaaS) platform.
  • Acquisition of ORTECH Consulting Inc., an engineering consulting firm specializing in Greenhouse Gas (GHG) reporting, emission testing, air quality testing and renewable energy/power consulting.
  • Acquisition of Efficiency Engineering Inc. (“EE Inc.”), which provides engineering services to industrial, municipal and commercial building owners across Canada. EE Inc. provides detailed energy efficiency analysis, energy audits, management of facility system solutions, electrical and mechanical design and energy conservation studies.
  • Acquisition of MCW Dimax Ltd. (“MCX”), a firm specializing in solutions for the application of energy software to analyze the management of complex heating, ventilation and cooling systems for large residential, commercial, and mission critical real estate owners.
  • Acquisition of CEM Specialties Inc. (“CEMSI”), a market leader in turn-key emission monitoring, equipment and solutions.

The company has also established entry into the North American cannabis market as a supplier of integrated energy efficiency solutions and technologies. Within this market, Kontrol is focused on assisting cannabis growers to reduce the cost of energy and support mission critical infrastructures. To date, Kontrol has secured two contracts to provide energy efficiency services with Licensed Producers in the Canadian cannabis sector.

The Kontrol Energy group of companies is currently saving its customers more than 40 million kilowatt hours of electricity per annum and providing a corresponding reduction in GHG emissions.

Kontrol’s management team includes CEO Paul Ghezzi, a leader in clean tech, renewable energy development, solar project financing and distributed generation. Ghezzi has global experience in power generation projects under Feed-in Tariff programs and Power Purchase Agreement programs for both commercial and utility-scale projects. COO Kristian Lavereau has more than 25 years of experience in the IT solutions (analytics and mobile computing), energy optimization and efficiency (intelligent control systems, solar PV, lighting). Claudio Del Vasto, CPA, CA | CFO, is a senior finance executive with an extensive background in corporate finance, strategy and business development.

Kontrol Energy Corp. (CSE: KNR), closed the day's trading session at $0.62, off by 4.62%, on 38,051 volume with 11 trades. The average volume for the last 3 months is 19,882 and the stock's 52-week low/high is $0.46/$1.58.

Recent News


Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTC: SGSI) is a leading telecommunications engineering and infrastructure services provider that operates through its subsidiaries, AW Solutions and ADEX Corp. To view the full article, visit:

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.


CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.25, off by 16.50%, on 12,200 volume with 6 trades. The average volume for the last 3 months is 20,232 and the stock's 52-week low/high is $0.18/$2.59.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.